Opko Health, Inc. (NASDAQ:OPK) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Other equities research analysts also recently issued reports about the stock. Cantor Fitzgerald set a $20.00 target price on shares of Opko Health and gave the company a “buy” rating in a report on Thursday, October 12th. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $16.00 target price on shares of Opko Health in a report on Monday, September 25th. Zacks Investment Research upgraded shares of Opko Health from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a report on Friday, July 21st. Jefferies Group LLC restated a “hold” rating and issued a $6.50 target price (down from $6.80) on shares of Opko Health in a report on Thursday, August 10th. Finally, J P Morgan Chase & Co downgraded shares of Opko Health from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $12.00 to $7.00 in a report on Thursday, September 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. Opko Health has a consensus rating of “Buy” and a consensus target price of $13.97.

Shares of Opko Health (OPK) opened at $5.50 on Friday. Opko Health has a twelve month low of $5.35 and a twelve month high of $12.15. The company has a quick ratio of 1.50, a current ratio of 1.67 and a debt-to-equity ratio of 0.02.

Opko Health (NASDAQ:OPK) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The company had revenue of $263.50 million during the quarter, compared to analysts’ expectations of $319.43 million. During the same quarter in the previous year, the firm posted ($0.03) earnings per share. Opko Health’s revenue for the quarter was down 11.6% compared to the same quarter last year. analysts forecast that Opko Health will post -0.19 EPS for the current fiscal year.

WARNING: “Opko Health, Inc. (OPK) Rating Lowered to Sell at BidaskClub” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/opko-health-inc-opk-rating-lowered-to-sell-at-bidaskclub/1694689.html.

In other news, CEO Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock in a transaction dated Monday, August 14th. The shares were acquired at an average cost of $6.15 per share, with a total value of $61,500.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $18,874,048.65. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Opko Health, Inc. bought 655,738 shares of Opko Health stock in a transaction dated Monday, October 30th. The shares were purchased at an average cost of $3.05 per share, for a total transaction of $2,000,000.90. Following the completion of the transaction, the insider now owns 6,678,752 shares of the company’s stock, valued at approximately $20,370,193.60. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 1,251,038 shares of company stock valued at $5,581,640. 40.19% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Public Employees Retirement Association of Colorado lifted its position in shares of Opko Health by 0.3% during the second quarter. Public Employees Retirement Association of Colorado now owns 73,417 shares of the biotechnology company’s stock worth $483,000 after purchasing an additional 216 shares in the last quarter. Pinnacle Associates Ltd. lifted its position in shares of Opko Health by 0.8% during the second quarter. Pinnacle Associates Ltd. now owns 50,000 shares of the biotechnology company’s stock worth $329,000 after purchasing an additional 397 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Opko Health by 1.7% during the second quarter. Ameriprise Financial Inc. now owns 53,788 shares of the biotechnology company’s stock worth $354,000 after purchasing an additional 896 shares in the last quarter. Prudential Financial Inc. lifted its position in shares of Opko Health by 6.1% during the second quarter. Prudential Financial Inc. now owns 24,511 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 1,400 shares in the last quarter. Finally, BB&T Securities LLC lifted its position in shares of Opko Health by 7.6% during the second quarter. BB&T Securities LLC now owns 20,600 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 1,460 shares in the last quarter. 22.57% of the stock is currently owned by institutional investors and hedge funds.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Analyst Recommendations for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.